Implementation of Genome Sequencing Assays
The implementation of whole-genome sequencing (WGS) as a clinical test has been a source of speculation, anticipation, and anecdotes for many years. The first clinical (CLIA-certified, CAP-accredited) laboratory to offer this test launched the service in 2009, and despite several significant challenges that still surround the offering and use of WGS for clinical applications, it has largely been embraced by an enthusiastic community of physicians and clinical laboratorians. In this chapter, we discuss the many considerations, caveats, challenges, and opportunities that must be addressed when implementing clinical WGS. Approaches to this implementation are also discussed. The chapter is organized into sections on test definition, staffing and training, infrastructure, validations, and interpretation and reporting considerations.
KeywordsGenome sequencing Next-generation sequencing (NGS) Clinical genomics Diagnostics Molecular pathology Molecular genetics Diagnostic odyssey
- Allele frequency
Proportion of a particular allele among all alleles for a gene
- Disease prevalence
Proportion of a population to have a condition
- Mendelian condition
A condition that is caused by variants within a single gene and that can be passed to offspring in an autosomal dominant or autosomal recessive pattern
Affected individual on whom testing is being performed
- 1.Genetic Testing Registry. https://www.ncbi.nlm.nih.gov/gtr/.
- 2.Clinical Laboratory Standards Institute (CLSI). Multiple standards publications relating to laboratory process and sequencing. http://www.clsi.org/standards/.
- 3.College of American Pathologists (CAP). Molecular pathology checklist; 2013. p. 1–67.Google Scholar
- 4.Chen B, Gagnon MC, Shahangian S, Anderson NL, Howerton DA, Boone DJ. Good laboratory practices for molecular genetic testing for heritable diseases and conditions: Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. MMWR Recomm Rep. 2009;58(RR-6):1–37.PubMedGoogle Scholar
- 9.Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, Friez MJ, Funke BH, Hegde MR, Lyon E, Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733–47.CrossRefGoogle Scholar
- 14.Bick D, Fraser PC, Gutzeit MF, Harris JM, Hambuch TM, Helbling DC, Jacob HJ, Kersten JN, Leuthner SR, May T, North PE, Prisco SZ, Schuler BA, Shimoyama M, Strong KA, Van Why SK, Veith R, Verbsky J, Weborg AM Jr, Wilk BM, Willoughby RE Jr, Worthey EA, Dimmock DP. Successful application of whole genome sequencing in a medical genetics clinic. J Pediatr Genet. 2017;6:61–76.PubMedGoogle Scholar
- 20.Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Vassy JL, Christensen KD, Schonman EF, et al. The impact of whole-genome sequencing on the primary care and outcomes of healthy adult patients. Ann Intern Med. 2017:1–12. https://doi.org/10.7326/M17-0188.
- 32.Garcia J, Tahiliani J, Johnson NM, et al. Clinical genetic testing for the cardiomyopathies and arrhythmias: a systematic framework for establishing clinical validity and addressing genotypic and phenotypic heterogeneity. Front Cardiovasc Med. 2016;3(4):228–11. https://doi.org/10.3389/fcvm.2016.00020.CrossRefGoogle Scholar
- 37.Online Mendelian Inheritance in Man, OMIM®. Baltimore, MD: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University; 2013. http://omim.org/.
- 38.Walsh M, Bell KM, Chong B, Creed E, Brett GR, Pope K, Thorne NP, Sadedin S, Georgeson P, Phelan DG, Day T, Taylor JA, Sexton A, Lockhart PJ, Kiers L, Fahey M, Macciocca I, Gaff CL, Oshlack A, Yiu EM, James PA, Stark Z, Ryan MM, Melbourne Genomics Health Alliance. Diagnostic and cost utility of whole exome sequencing in peripheral neuropathy. Ann Clin Transl Neurol. 2017;4(5):318–25.CrossRefGoogle Scholar
- 39.Vissers LE, van Nimwegen KJ, Schieving JH, Kamsteeg EJ, Kleefstra T, Yntema HG, Pfundt R, van der Wilt GJ, Krabbenborg L, Brunner HG, van der Burg S, Grutters J, Veltman JA, Willemsen MA. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017;19(9):1055–63. https://doi.org/10.1038/gim.2017.1.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Riggs ER, Wain KE, Riethmaier D, et al. Towards a Universal Clinical Genomics Database: The 2012 International Standards for Cytogenomic Arrays (ISCA) Consortium Meeting. Human mutation. 2013;34(6):915-919. https://doi.org/10.1002/humu.22306.
- 44.Kalia SS, Adelman K, Bale S, Chung WK, Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR, McKalvey KD, Ormond KE, Richards CS, Vlangros CN, Watson M, Martin CL, Miller DT. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:249–55.CrossRefGoogle Scholar